AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27317797 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) during acute HIV infection (AHI)
Number of subjects: 234
Study 27318133 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-PBR28 binding in amyloid-positive patients
Number of subjects: 22
Study 27318133 — intervention group
Group type: COMPARATOR
Intervention: Control group (amyloid-negative)
Number of subjects: 22
Study 27318133 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-PBR28 binding in patients with clinical progression
Number of subjects: 22
Study 27318133 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-PBR28 binding
Number of subjects: 22
Study 27319011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 0
Study 27319011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27319305 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic case finding approach for COPD
Number of subjects: 1743
Study 27319305 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple score for detecting COPD
Number of subjects: 1743
Study 27319305 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted score for detecting COPD
Number of subjects: 1743
Study 27321869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (opioids, midazolam, anticholinergics)
Number of subjects: 152
Study 27321869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 152
Study 27321972 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal age (median 50 years)
Number of subjects: 426
Study 27321972 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 426
Study 27321972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction, female sex, ST elevation myocardial infarction
Number of subjects: 426
Study 27322029 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 1.4 g protein/kg/d during controlled diet and training, followed by variable test diets providing 0.2-2.8 g·kg-1·d-1 protein after exercise.
Number of subjects: 6
Study 27322029 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline amino acid mixture based on egg protein with [1-13C]phenylalanine.
Number of subjects: 6
Study 27322029 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diets with varying protein amounts post-exercise.
Number of subjects: 6
Study 27322029 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended protein intake compared to RDA and current recommendations for endurance athletes.
Number of subjects: 6
Study 27322733 — intervention group
Group type: EXPERIMENTAL
Intervention: Actical accelerometer thresholds for sedentary/light activity
Number of subjects: 28
Study 27322733 — intervention group
Group type: EXPERIMENTAL
Intervention: Actical accelerometer thresholds for light/moderate activity
Number of subjects: 28
Study 27322733 — intervention group
Group type: EXPERIMENTAL
Intervention: Actical accelerometer thresholds for moderate/vigorous activity
Number of subjects: 28
Study 27322859 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy (3D-CRT) APBI, 34-38.5 Gy in 10 fractions over 5 days
Number of subjects: 141
Study 27322906 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcichew D3 500/400
Number of subjects: 276
Study 27322906 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcichew D3 500/800
Number of subjects: 276
Study 27322906 — intervention group
Group type: COMPARATOR
Intervention: Adcal-D3
Number of subjects: 276
Study 27322906 — intervention group
Group type: COMPARATOR
Intervention: Kalcipos-D
Number of subjects: 276
Study 27323698 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical definitions of individual benefit of medical or behavioral treatment using generalized linear mixed-effects models.
Number of subjects: 0
Study 27323698 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear mixed-effects models applied to clinical trial data.
Number of subjects: 0
Study 27323698 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from the Sequenced Treatment Alternatives to Relieve Depression clinical trial.
Number of subjects: 0
Study 27323698 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from a clinical trial of respiratory treatments.
Number of subjects: 0
Study 27324108 — intervention group
Group type: COMPARATOR
Intervention: Olaparib
Number of subjects: 0
Study 27324671 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27324719 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)) for up to 2.5 years
Number of subjects: 300
Study 27324768 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (standard dosing)
Number of subjects: 52
Study 27324768 — intervention group
Group type: COMPARATOR
Intervention: Simulated patients (n = 67,000)
Number of subjects: 52
Study 27325219 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 201
Study 27325219 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for multiple attacks
Number of subjects: 201
Study 27325219 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for pancreas divisum
Number of subjects: 201
Study 27325219 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for sphincter of Oddi dysfunction (SOD)
Number of subjects: 201
Study 27325219 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after a single idiopathic attack with negative EUS
Number of subjects: 201
Study 27325219 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 201
Study 27325286 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]5-HTP PET
Number of subjects: 8
Study 27325334 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA1-like profile by array comparative genomic hybridization (aCGH) testing
Number of subjects: 3000
Study 27325334 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA1-like profile by multiplex ligation-dependent probe amplification (MLPA) testing
Number of subjects: 3000
Study 27325334 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy 1 followed by X-inactive specific transcript gene (XIST) and tumor suppressor p53 binding protein (53BP1) testing
Number of subjects: 3000
Study 27325334 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy 2 followed by XIST and 53BP1 testing
Number of subjects: 3000
Study 27325409 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (32-34 °C) for 24 hours with propofol sedation
Number of subjects: 270
Study 27325409 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 270
Study 27325604 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D
Number of subjects: 0
Study 27325685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus Capecitabine (Lapatinib 1,250 mg daily and Capecitabine 1,000 mg/m² twice daily for 14 days)
Number of subjects: 68
Study 27325685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus Capecitabine
Number of subjects: 68
Study 27325856 — intervention group
Group type: COMPARATOR
Intervention: MMR normal group
Number of subjects: 1024
Study 27325856 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenetic MMR defects
Number of subjects: 1024
Study 27325856 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable MMR mutation cases
Number of subjects: 1024
Study 27325856 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR defects in EECs
Number of subjects: 1024
Study 27325859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) administered at a planned dose of 50.4 Gy in 28 fractions.
Number of subjects: 45
Study 27325859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemithoracic IMPRINT
Number of subjects: 45
Study 27326168 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 45
Study 27326168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 27326241 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise ECG
Number of subjects: 0
Study 27326819 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) and resistance training (RT) for 1 year
Number of subjects: 31
Study 27326862 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogue regimen
Number of subjects: 0
Study 27326862 — intervention group
Group type: COMPARATOR
Intervention: Human insulin regimen
Number of subjects: 0
Study 27328169 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine with nonmydriatic cameras
Number of subjects: 424
Study 27328699 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP >3.0 mg/L
Number of subjects: 3044
Study 27328699 — intervention group
Group type: COMPARATOR
Intervention: hsCRP <1 mg/L
Number of subjects: 3044
Study 27328702 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke emergency mobile (specialized stroke ambulance)
Number of subjects: 430
Study 27328702 — intervention group
Group type: COMPARATOR
Intervention: Conventional emergency medical service
Number of subjects: 430
Study 27328985 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD)
Number of subjects: 35
Study 27329247 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03446962 7 mg/kg intravenously biweekly
Number of subjects: 24
Study 27329447 — intervention group
Group type: EXPERIMENTAL
Intervention: Men in upright position
Number of subjects: 334
Study 27329447 — intervention group
Group type: EXPERIMENTAL
Intervention: Men in supine position
Number of subjects: 334
Study 27329447 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability in men
Number of subjects: 334
Study 27329447 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of men and postmenopausal women (n=76, aged >55 years)
Number of subjects: 334
Study 27329686 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-emotional content
Number of subjects: 0
Study 27329686 — intervention group
Group type: EXPERIMENTAL
Intervention: Social content
Number of subjects: 0
Study 27329686 — intervention group
Group type: EXPERIMENTAL
Intervention: Object stimuli
Number of subjects: 0
Study 27330001 — intervention group
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain (prophylactic regimen)
Number of subjects: 175
Study 27330001 — intervention group
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain (on-demand regimen)
Number of subjects: 175
Study 27330001 — intervention group
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain (surgical prophylaxis)
Number of subjects: 175
Study 27330024 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (≥2 mm RTT)
Number of subjects: 40
Study 27330024 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (<2 mm RTT)
Number of subjects: 40
Study 27330024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 27330166 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPA positive patients
Number of subjects: 1996
Study 27330166 — intervention group
Group type: COMPARATOR
Intervention: ACPA negative patients
Number of subjects: 1996
Study 27330809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus nivolumab
Number of subjects: 1
Study 27330808 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose denileukin diftitox (18 mcg/kg) prior to vaccination
Number of subjects: 17
Study 27330808 — intervention group
Group type: COMPARATOR
Intervention: 4-peptide vaccine (Melan-A, gp100, MAGE3 and NA17 with GM-CSF emulsified in Montanide) alone
Number of subjects: 17
Study 27331367 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of LPS via MB2 nebulizer (3.2 μm)
Number of subjects: 3
Study 27331367 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of LPS via Pari nebulizer (7.9 μm)
Number of subjects: 3
Study 27331367 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of LPS via Microcirrus nebulizer (2.0 μm)
Number of subjects: 3
Study 27331367 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of large droplets of LPS
Number of subjects: 3
Study 27331367 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response
Number of subjects: 3
Study 27331585 — intervention group
Group type: EXPERIMENTAL
Intervention: ShangRing circumcision (VMMC)
Number of subjects: 1149
Study 27332703 — intervention group
Group type: EXPERIMENTAL
Intervention: LINKAGE intervention (6 group-based, manual-guided sessions on patient engagement and health information technology)
Number of subjects: 503
Study 27332703 — intervention group
Group type: EXPERIMENTAL
Intervention: LINKAGE intervention
Number of subjects: 503
Study 27332703 — intervention group
Group type: EXPERIMENTAL
Intervention: LINKAGE intervention (full components)
Number of subjects: 503
Study 27332703 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 503
Study 27332992 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD group
Number of subjects: 742
Study 27332992 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 742
Study 27333938 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (self-regulated exercise)
Number of subjects: 50
Study 27333947 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) administered as a single 600 mg dose followed by multiple doses to steady-state.
Number of subjects: 57
Study 27333947 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz concentrations exceeding 0.4 μg/mL.
Number of subjects: 57
Study 27334213 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous core needle biopsy (PNB) of axillary sentinel lymph nodes (SLNs)
Number of subjects: 25
Study 27334213 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincision axillary ultrasound
Number of subjects: 25
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal heart rate (HR) in girls
Number of subjects: 339
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised physical activity in girls
Number of subjects: 339
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass in girls
Number of subjects: 339
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Errors in static balance test in girls
Number of subjects: 339
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised physical activity in boys
Number of subjects: 339
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting HR in boys
Number of subjects: 339
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand grip strength in boys
Number of subjects: 339
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Errors in static balance test in boys
Number of subjects: 339
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized football in boys
Number of subjects: 339
Study 27334557 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised trampoline jumping in boys
Number of subjects: 339
Study 27334671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol/amlodipine FDC 5/5 mg OD
Number of subjects: 200
Study 27334671 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol monotherapy failure
Number of subjects: 200
Study 27334671 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine monotherapy failure
Number of subjects: 200
Study 27335027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks) in combination with chemotherapy
Number of subjects: 314
Study 27335060 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with neonatal AKI (AKI-C)
Number of subjects: 74
Study 27335060 — intervention group
Group type: COMPARATOR
Intervention: Control children without AKI
Number of subjects: 74
Study 27335060 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort (both groups)
Number of subjects: 74
Study 27335651 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 72
Study 27335651 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated position
Number of subjects: 72
Study 27335883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (5 mgs/kg)
Number of subjects: 20
Study 27335883 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 27336356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone administration
Number of subjects: 38
Study 27336786 — intervention group
Group type: EXPERIMENTAL
Intervention: TIIV
Number of subjects: 0
Study 27336786 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIIV
Number of subjects: 0
Study 27336786 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 27337418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal wakefulness at 4:00 am
Number of subjects: 65
Study 27337418 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnographically documented sleep disruption
Number of subjects: 65
Study 27338133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal TSH levels (≤2.5 mU/L)
Number of subjects: 132
Study 27338133 — intervention group
Group type: COMPARATOR
Intervention: High-normal TSH levels (>2.5 mU/L)
Number of subjects: 132
Study 27338143 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (etanercept)
Number of subjects: 70
Study 27338143 — intervention group
Group type: EXPERIMENTAL
Intervention: PsoA patients
Number of subjects: 70
Study 27338143 — intervention group
Group type: EXPERIMENTAL
Intervention: TWEAK-binding IgG autoantibodies
Number of subjects: 70
Study 27338191 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training, details on dosage and duration not available
Number of subjects: 0
Study 27338778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 15132
Study 27338778 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab-plus-methotrexate
Number of subjects: 15132
Study 27338778 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 15132
Study 27338778 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (in pregnant women)
Number of subjects: 15132
Study 27338994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 160
Study 27338994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer + Goal Prompt
Number of subjects: 160
Study 27338994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer + Goal Prompt + Theory-informed Texts
Number of subjects: 160
Study 27338994 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 160
Study 27339489 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous direct annuloplasty
Number of subjects: 71
Study 27339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine MRI assessment
Number of subjects: 213
Study 27339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cord compression
Number of subjects: 213
Study 27339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 213
Study 27339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 213
Study 27339555 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical complications
Number of subjects: 213
Study 27339614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambda-IFN/RBV/DCV for 12 weeks (cohort A)
Number of subjects: 51
Study 27339614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambda-IFN/RBV/DCV for 12 weeks followed by Lambda-IFN/RBV for an additional 12 weeks (cohort B)
Number of subjects: 51
Study 27339787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Clearance Index (LCI)
Number of subjects: 110
Study 27339787 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Mid-Expiratory Flow (MMEF)
Number of subjects: 110
Study 27339787 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LCI during bronchiectasis exacerbations (BEs)
Number of subjects: 110
Study 27339787 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in MMEF% predicted during bronchiectasis exacerbations (BEs)
Number of subjects: 110
Study 27339787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses in mild, moderate and severe bronchiectasis
Number of subjects: 110
Study 27339787 — intervention group
Group type: EXPERIMENTAL
Intervention: MMEF% predicted
Number of subjects: 110
Study 27340399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigtail catheter insertion
Number of subjects: 60
Study 27340749 — intervention group
Group type: EXPERIMENTAL
Intervention: Olipudase alfa (recombinant human ASM) administered every 2 weeks for 26 weeks
Number of subjects: 5
Study 27340749 — intervention group
Group type: EXPERIMENTAL
Intervention: Olipudase alfa (recombinant human ASM)
Number of subjects: 5
Study 27342239 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 5 mg
Number of subjects: 21
Study 27342239 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 10 mg
Number of subjects: 21
Study 27342239 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 15 mg
Number of subjects: 21
Study 27342412 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakthrough cancer pain (BTP)
Number of subjects: 978
Study 27342412 — intervention group
Group type: COMPARATOR
Intervention: No BTP
Number of subjects: 978
Study 27342580 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary TIMP-2 and IGFBP7 biomarker test
Number of subjects: 0
Study 27342743 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous use of hormonal treatment for endometriosis
Number of subjects: 1008
Study 27342743 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous surgery for endometriosis
Number of subjects: 1008
Study 27342743 — intervention group
Group type: EXPERIMENTAL
Intervention: Living or working in a city or by a busy area
Number of subjects: 1008
Study 27342748 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegaven (intravenous infusion of omega-3 polyunsaturated fatty acids)
Number of subjects: 21
Study 27342758 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered IGIV-C (200-600 mg/kg per infusion every 3-4 weeks)
Number of subjects: 12
Study 27342758 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously administered IGIV-C (calculated using a conversion factor of 1.37 times the prior IV dose)
Number of subjects: 12
Study 27342758 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered IGIV-C
Number of subjects: 12